Patents by Inventor Joseph Vacca

Joseph Vacca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961202
    Abstract: Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: March 30, 2021
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, EXPANSION THERAPEUTICS, INC.
    Inventors: Matthew Disney, Timothy Allen Blizzard, Suzanne Rzuczek, John Ndungu, Joseph Vacca, Andy Jennings, Alexei Pushechnikov
  • Patent number: 10960003
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: March 30, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
  • Patent number: 10906881
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 2, 2021
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20210017167
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 4, 2020
    Publication date: January 21, 2021
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20200397760
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat pancreatic cancer.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 24, 2020
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • Publication number: 20200354340
    Abstract: The present invention provides pyrazole derivatives of Formula (I), and in particular N1-(4-(5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl) pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as casein kinase 1 (CK1) and/or interleukin 1 receptor associated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders.
    Type: Application
    Filed: January 30, 2018
    Publication date: November 12, 2020
    Inventors: Dansu Li, Irit Snir-Alkalay, Joseph Vacca, Yinon Ben-Neriah, Avanthika Venkatachalam
  • Publication number: 20200306229
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula: in combination with a PARP inhibitor, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: March 25, 2020
    Publication date: October 1, 2020
    Inventors: Alfredo C. CASTRO, Melinda DAY, Tyler MACLAY, Casey Cameron MCCOMAS, Kevin MILLS, Joseph VACCA
  • Publication number: 20200291014
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: March 12, 2020
    Publication date: September 17, 2020
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • Publication number: 20200216437
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • Patent number: 10676470
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 9, 2020
    Assignee: CORTEXYME, INC.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20200129484
    Abstract: This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.
    Type: Application
    Filed: July 11, 2018
    Publication date: April 30, 2020
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA
  • Publication number: 20200131189
    Abstract: Inhibitors of CDK9 that are pyrazolo[1,5-a]pyrimidine derivatives and salts thereof, corresponding to formula (I):
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Inventors: Peter MIKOCHIK, Joseph VACCA, David FREEMAN, Andrew S. TASKER
  • Patent number: 10590122
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: March 17, 2020
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Publication number: 20190365759
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Application
    Filed: August 12, 2019
    Publication date: December 5, 2019
    Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
  • Publication number: 20190322659
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 24, 2019
    Applicant: Cortexyme, Inc.
    Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Patent number: 10376511
    Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: August 13, 2019
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem LTD.
    Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
  • Patent number: 10336746
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: July 2, 2019
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Alfredo C. Castro, Casey Cameron McComas, Joseph Vacca, Tyler Maclay
  • Publication number: 20190194182
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: December 31, 2018
    Publication date: June 27, 2019
    Inventors: Alfredo C. CASTRO, Casey Cameron MCCOMAS, Joseph VACCA, Tyler MACLAY
  • Patent number: 10301301
    Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 28, 2019
    Assignee: CORTEXYME, INC.
    Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
  • Publication number: 20190152924
    Abstract: Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.
    Type: Application
    Filed: November 16, 2018
    Publication date: May 23, 2019
    Inventors: Matthew Disney, Timothy Allen Blizzard, Suzanne Rzuczek, John Ndungu, Joseph Vacca, Andy Jennings, Alexei Pushechnikov